Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer

Lung Cancer. 2005 Dec;50(3):417-8. doi: 10.1016/j.lungcan.2005.07.004. Epub 2005 Aug 29.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • ErbB Receptors / genetics
  • Erlotinib Hydrochloride
  • Female
  • Gefitinib
  • Humans
  • Intracellular Signaling Peptides and Proteins / therapeutic use*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Male
  • Middle Aged
  • Mutation
  • Quinazolines / therapeutic use*

Substances

  • Antineoplastic Agents
  • Intracellular Signaling Peptides and Proteins
  • Quinazolines
  • protein kinase modulator
  • Erlotinib Hydrochloride
  • ErbB Receptors
  • Gefitinib